Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 21 Jan 2026 | Eric Mamer Director-General | General discussion on DG ENV priorities | SRC |
| 21 Jan 2026 | Eric Mamer Director-General | General discussion on DG ENV priorities | — |
| 21 Mar 2025 | Stéphane Séjourné Executive Vice-President | - Marché intérieur - Compétitivité - Sécurité économique - Simplification - Relation USA / Europe | SRC |
| 21 Mar 2025 | Stéphane Séjourné Executive Vice-President | - Marché intérieur - Compétitivité - Sécurité économique - Simplification - Relation USA / Europe | — |
| 21 Mar 2025 | Sacha Halphen Cabinet member | - Marché intérieur - Compétitivité - Sécurité économique - Simplification - Relation USA / Europe | SRC |
| 02 Mar 2023 | Mairead McGuinness Commissioner | Introductory meeting | — |
| 02 Mar 2023 | Mairead McGuinness Commissioner | Introductory meeting | SRC |
| 12 Oct 2022 | Stella Kyriakides Commissioner | Exchange on-going cooperation; Europe's Beating Cancer plan - exchange on innovation in the future of cancer treatment and care | SRC |
| 12 Oct 2022 | Stella Kyriakides Commissioner | Exchange on-going cooperation; Europe's Beating Cancer plan - exchange on innovation in the future of cancer treatment and care | — |
| 09 Sept 2022 | Margaritis Schinas Vice-President | Pharma Strategy | — |
| 09 Sept 2022 | Margaritis Schinas Vice-President | Pharma Strategy | SRC |
| 26 Nov 2021 | Ursula von der Leyen President | Meeting with CEO of Pfizer | SRC |
| 26 Nov 2021 | Ursula von der Leyen President | Meeting with CEO of Pfizer | — |
| 26 Oct 2021 | Kevin Keary Cabinet member | Pharmaceutical sector – trade related issues | SRC |
| 26 Oct 2021 | Elina Melngaile Cabinet member | Pharmaceutical sector – trade related issues | — |
| 26 Oct 2021 | Kevin Keary Cabinet member | Pharmaceutical sector – trade related issues | — |
| 26 Oct 2021 | Caroline Boeshertz Cabinet member | Pharmaceutical sector – trade related issues | SRC |
| 26 Oct 2021 | Elina Melngaile Cabinet member | Pharmaceutical sector – trade related issues | SRC |
| 18 Oct 2021 | Roberto Reig Rodrigo Cabinet member | Call with Pfizer’s Regional President for Vaccines, Mr. Sinan Atlig, to discuss the implementation of COVID-19 vaccines Advance Purchase Agreement | — |
| 18 Oct 2021 | Giorgos Rossides Cabinet member | Call with Pfizer’s Regional President for Vaccines, Mr. Sinan Atlig, to discuss the implementation of COVID-19 vaccines Advance Purchase Agreement | — |
| 18 Oct 2021 | Roberto Reig Rodrigo Cabinet member | Call with Pfizer’s Regional President for Vaccines, Mr. Sinan Atlig, to discuss the implementation of COVID-19 vaccines Advance Purchase Agreement | SRC |
| 18 Oct 2021 | Giorgos Rossides Cabinet member | Call with Pfizer’s Regional President for Vaccines, Mr. Sinan Atlig, to discuss the implementation of COVID-19 vaccines Advance Purchase Agreement | SRC |
| 16 Jun 2021 | Margaritis Schinas Vice-President | Supply chains for medicines | — |
Mission & Goals
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.
EU Legislative Interests
Revision of the EU pharmaceutical legislation, EU Biotech Act, EU Critical Medicines Act, Urban Wastewater Treatment Directive, Paediatric & Orphan Medicinal Products, Vaccination policy, Health Technology Assessment, Chemical Policy, IHI and research programs, EU trade policy, industrial policy, research and innovation policy, pandemic preparedness.
Communication Activities
www.pfizereupolicy.eu
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
In 2025 Pfizer was a member of: EFPIA, Vaccines Europe, EuropaBio, Amcham EU, BusinessEurope, European Policy Centre, European Business Summits, Friends of Europe.
Additional Information
The amount declared in answer (c) includes: relevant percentage of trade associations' work, consultants as declared, percentage of colleagues' fully loaded salary and office expenses.